CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

Abstract The prognosis of adults with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains dismal even at this day and age. With salvage chemotherapy, only 29% (range 18 to 44%) of the patients with R/R ALL can be induced into complete remission (CR), with a median overall survival (...

Full description

Bibliographic Details
Main Authors: Li-Na Zhang, Yongping Song, Delong Liu
Format: Article
Language:English
Published: BMC 2018-03-01
Series:Journal of Hematology & Oncology
Subjects:
Chimeric antigen receptor
CAR-T
Cancer immunotherapy
Blinatumomab
Online Access:http://link.springer.com/article/10.1186/s13045-018-0593-5

Internet

http://link.springer.com/article/10.1186/s13045-018-0593-5

Similar Items